ReviewJournal of clinical medicine2023
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06439615 (The Treatment Effect of Baricitinib for the Secondary Pulmonary Complications Following Spontaneous Subarachnoid Hemorrhage), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Treatment Effect of Baricitinib for the Secondary Pulmonary Complications Following Spontaneous Subarachnoid Hemorrhage
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial.BMC medicine · 2025Trial
- A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis.CPT: pharmacometrics & systems pharmacology · 2024Trial
- Filgotinib in Moderate to Severe Rheumatoid Arthritis in a Real-World Setting: Up to 6-Month Effectiveness, Patient-Reported Outcomes, and Persistence, and up to 24-Month Safety from More than 1400 Patients in the FILOSOPHY and PARROTFISH Studies.Rheumatology and therapy · 2026Article
- Pain Reduction Improves Adherence, Quality of Life, and Work Capacity in Rheumatoid Arthritis Patients Receiving Baricitinib: Czech ATTRA Registry Analysis.Rheumatology and therapy · 2026Article
- Pathogenesis and advances in immunotherapy for type 1 diabetes treatment.Biotechnology reports (Amsterdam, Netherlands) · 2026Review
- Unusual Neuropsychiatric Presentation ofDiseases (Basel, Switzerland) · 2025Article
- Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib.Journal of clinical medicine · 2025Article
- Treatment of Moderate-to-severe Atopic Dermatitis with Upadacitinib: Results from an Interim Analysis of the TREATgermany Registry.Acta dermato-venereologica · 2025Article
- Evaluation of Olive Oil-Based Formulations Loaded with Baricitinib for Topical Treatment of Alopecia Areata.Pharmaceutics · 2025Article
- Comparative Effectiveness and Safety of the JAK Inhibitors and Biologic Disease-Modifying Antirheumatic Drugs in Treating Children With Nonsystemic Juvenile Idiopathic Arthritis: A Bayesian Meta-Analysis of Randomized Controlled Trials.ACR open rheumatology · 2025Article
- Baricitinib represses the myocardial fibrosis via blocking JAK/STAT and TGF-β1 pathways in vivo and in vitro.BMC cardiovascular disorders · 2025Article
- Remote-Customized Telecontrol for Patients with Rheumatoid Arthritis: The iARPlus (Innovative Approach in Rheumatology) Initiative.Journal of personalized medicine · 2025Article
- JAK-STAT Signaling in Autoimmunity and Cancer.ImmunoTargets and therapy · 2025Review
- Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons.International journal of molecular sciences · 2024Article
- Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.Expert review of clinical immunology · 2024Review
- The Real-World Effectiveness, Persistence, Adherence, and Safety of Janus Kinase Inhibitor Baricitinib in Rheumatoid Arthritis: A Long-Term Study.Journal of clinical medicine · 2024Article
- Exploring the Therapeutic Potential ofPharmaceuticals (Basel, Switzerland) · 2024Article
- JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions.Molecular biomedicine · 2023Review
- Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy.Frontiers in pharmacology · 2023Review
- JAK inhibitors and black box warnings: what is the future for JAK inhibitors?Expert review of clinical immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 6 countries.
Funding
Abstract
Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved as monotherapy or in combination with methotrexate for treating adults with moderate-to-severe active rheumatoid arthritis (RA) and provides improvements in clinical signs, symptoms and patient-reported outcomes. Currently, baricitinib is approved for treating RA in more than 75 countries. In several pivotal Phase II and III RA trials (RA-BALANCE, RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BEYOND), up to seven years of baricitinib treatment was well tolerated and provided rapid and sustained efficacy, which was confirmed in real-world settings. Safety signals for another JAK inhibitor, tofacitinib, have emerged, as observed in the post-marketing Phase IIIb/IV trial Oral Rheumatoid Arthritis Trial (ORAL) Surveillance; safety signals were subsequently highlighted in a retrospective study of baricitinib and consequently new recommendations and warnings and precautions for all JAK inhibitors have been issued. Ongoing studies to further characterise and clarify the benefit:risk of JAK inhibitors include registries and controlled trials. This capstone review summarises clinical and real-world data outlining the benefit:risk profile of baricitinib, confirming that the improved disease activity and physical function of patients with RA treated with this JAK inhibitor observed in clinical trials is translated into effectiveness in clinical practice, with a low rate of discontinuations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.